Virological Failure in HIV to Triple Therapy With Dolutegravir-Based Firstline Treatment: Rare but Possible
Virological Failure in HIV to Triple Therapy With Dolutegravir-Based Firstline Treatment: Rare but Possible
复制标题
DOI：
10.1093/ofid/ofy332
复制
发表时间：
2019-01-01
影响因子：
4.2
通讯作者：
Garcia, F.
中科院分区：
文献类型：
--
作者：
Pena, M. J.;Chueca, N.;Garcia, F.
我们描述了一例在使用富马酸替诺福韦二吡呋酯/恩曲他滨/多替拉韦每日两次进行初始治疗期间出现病毒学失败的病例，同时使用利福平治疗葡萄球菌感染，出现了R263K + E157Q突变，且血浆多替拉韦水平较低。将利福平与多替拉韦一起使用可能需要更密切的随访，并且如果可能的话，应该监测血浆多替拉韦水平。
We describe a case of virological failure during initial treatment with tenofovir disoproxil fumarate/emtricitabine/dolutegravir twice daily, with concomitant rifampin treatment of staphylococcal infection, selection of R263K+E157Q, and low plasma dolutegravir levels. Using rifampin together with dolutegravir may require closer follow-up, and, if possible, plasma dolutegravir levels should be monitored.